BioSpace News Archive

Graphite Bio, Inc. announced today that members of the management team will participate in a fireside chat at the Jefferies Gene Therapy/Editing Summit on Thursday, Oct. 28, 2021, at 4:30 p.m. ET.

Teva Pharmaceuticals today announced 25 presentations examining new Phase 3 clinical data, post hoc analyses and open-label extension (OLE) studies for both TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) and AUSTEDO® (deutetrabenazine) tablets.

Astria Therapeutics, Inc. today announced that it will share new preclinical results for STAR-0215 in a presentation titled “STAR-0215 Is a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor for the Potential Treatment of HAE” at the 2021 American College of Allergy, Asthma and Immunology Annual Scientific Meeting

Arcturus Therapeutics Holdings Inc. announced the appointments of Dr. Nirdosh Jagota as the Chief Regulatory Officer and Dr. Dushyant B. Varshney as the Chief Technology Officer.

Vericel Corporation today announced the following webcast and conference call to discuss its third-quarter 2021 financial results and business highlights.

Indivior PLC (LON: INDV) today announced the presentation of new data from multiple posters and presentations at the Canadian Society of Addiction Medicine – La Société Médicale Canadienne sur L’addiction (CSAM-SMCA) 2021 Scientific Conference, taking place virtually October 21-23, 2021 .

Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers.

NuProbe scientists and collaborators recently announced research demonstrating the accurate quantitation of somatic mutations below 0.01% variant allele frequency (VAF).

Audicus, responded today to the FDA’s proposed rule to establish a new category of over-the-counter (OTC) hearing aids.

Today, the Global Down Syndrome Foundation (GLOBAL) announced that their lead Alzheimer’s scientist and colleagues were awarded a $4.6 million, five-year grant by the National Institutes of Aging to study whether a potential Alzheimer’s disease treatment is safe and effective in improving cognition function in young adults with Down syndrome.